Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Fate Therapeutics Inc
FATECurrent price
1.28 USD
-0.04 USD (-3.03%)
Last closed
1.33 USD
Company
www.fatetherapeutics.com
ISIN
US31189P1021
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
154 715 408 USD
Yield for 12 month
-68.32 %
1Y
3Y
5Y
10Y
15Y
FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 12278 Scripps Summit Drive, San Diego, CA, United States, 92131
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6.39 USDP/E ratio
–Dividend Yield
–Current Year
+13 631 000 USD
Last Year
+63 533 000 USD
Current Quarter
+1 860 000 USD
Last Quarter
+3 074 000 USD
Current Year
+13 631 000 USD
Last Year
-98 163 000 USD
Current Quarter
+1 860 000 USD
Last Quarter
+3 074 000 USD
Key Figures FATE
1 year
3 years
5 years
10 years
EBITDA
-176 576 992 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-25.81 %
PEG Ratio
–
Return On Equity TTM
-54.21 %
Wall Street Target Price
6.39 USD
Revenue TTM
13 631 000 USD
Book Value
2.80 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
11.00 %
Dividend Yield
–
Gross Profit TTM
-104 900 000 USD
Earnings per share
-1.64 USD
Diluted Eps TTM
-1.64 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics FATE
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History FATE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation FATE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
20.39
Price Sales TTM
11.35
Enterprise Value EBITDA
-2.59
Price Book MRQ
0.48
Financials FATE
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators FATE
For 52 weeks
0.66 USD
5.92 USD
50 Day MA
1.06 USD
Shares Short Prior Month
14 571 003
200 Day MA
2.43 USD
Short Ratio
7.52
Shares Short
16 374 114
Short Percent
16.38 %
BeatStart